Table 2.
Proportion of Subjects With Local Solicited Symptoms During Days 1–7 After Receipt of Placebo, Inactivated Influenza Vaccine (IIV), and Respiratory Syncytial Virus (RSV) Vaccine, by Study Group
| Symptom | Placebo and IIV Group, Recipients, No. (%) (n = 948) |
RSV Vaccine and IIV Group, Recipients, No. (%) (n = 946) | All IIV Recipients, No. (%)a (n = 1894) | ||
|---|---|---|---|---|---|
| Placebo | IIV | RSV Vaccine | IIV | ||
| Any | 199 (21.0) | 429 (45.3) | 459 (48.5) | 393 (41.5) | 822 (43.4) |
| Pain at injection site | 126 (13.3) | 261 (27.5) | 299 (31.6) | 266 (28.1) | 527 (27.8) |
| Tenderness/soreness at injection site | 147 (15.5) | 360 (38.0) | 383 (40.5) | 336 (35.5) | 696 (36.7) |
| Redness at injection site | 7 (0.7) | 50 (5.3) | 65 (6.9) | 40 (4.2) | 90 (4.8) |
| Swelling at injection site | 4 (0.4) | 50 (5.3) | 49 (5.2) | 32 (3.4) | 82 (4.3) |
Abbreviations: IIV, inactivated influenza vaccine; RSV, respiratory syncytial virus.
aData are for all subjects who received IIV.